Cite

HARVARD Citation

    Yimer, H. et al. (2022). Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. Leukemia & lymphoma. 63 (10), pp. 2383-2392. [Online]. 
  
Back to record